AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05493501
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered by IV Infusion over 4 fixed cycles per prescribing information.
Trial: NCT04895917
Drug: daratumumab and pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patient eligible to enter the study will receive 6 cycles of 28 days of subcutaneous Daratumumab (1800 mg SC) and oral pomalidomide 4 mg from day 1 to day 21. During cycle 1 and 2, Daratumumab will be administered weekly at days 1, 8, 15, and 22 then from cycle 3 to 6, Daratumumab will be administered every other week at days 1 and 15.
Trial: NCT06757517
Drug: Oxytocin nasal spray
RxNorm normalized name: oxytocin Nasal Spray
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Syntocinon contains synthetic oxytocinfor intranasal use, 6.7 microg (4 IU) per dose. We are planning to use 4 insufflations (16 IU) three times daily (i.e. a total daily dose of 48 IU).
Trial: NCT06757517
Drug: Saline (NaCl 0,9 %) (placebo)
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline intranasal placebo comparator
Trial: NCT06773936
Drug: Post-Remission
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blinatumomab, Dasatinib, Methotrexate and Dexamethasone
Trial: NCT06773936
Drug: Maintenance
RxNorm normalized name: Xcopri Maintenance Pack
DrugBank: Cenobamate (DB06119)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Asciminib, Dasatinib, Prednisone, and Methotrexate
Trial: NCT06752759
Drug: nebulized ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The formulation of the study drug is administered via nebulizer in which the participants inhales the study drug. The dosage is calculated by body weight (1.5mg/kg).
Trial: NCT06487572
Drug: Risankizumab
RxNorm normalized name: RISANKIZUMAB
DrugBank: Risankizumab (DB14762)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous (IV) Infusion
Trial: NCT06487572
Drug: Risankizumab
RxNorm normalized name: RISANKIZUMAB
DrugBank: Risankizumab (DB14762)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous (SC) Injection
Trial: NCT06611436
Drug: BE-101
RxNorm normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV Infusion of BE-101 dose from Dose Level 1
Trial: NCT06611436
Drug: BE-101
RxNorm normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV Infusion of BE-101 dose from Dose Level 2
Trial: NCT06611436
Drug: BE-101
RxNorm normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV Infusion of BE-101 dose from Dose Level 3
Trial: NCT06611436
Drug: BE-101
RxNorm normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV Infusion of BE-101 with optimal dose selected from Part 1 Dose Escalation
Trial: NCT06744868
Drug: THDBH120 injection (SAD)
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants received escalating single doses of THDBH120 by subcutaneous injection.
Trial: NCT06740552
Drug: Evolocumab
RxNorm normalized name: Evolocumab
DrugBank: Evolocumab (DB09303)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Evolocumab 140mg every two weeks
Trial: NCT06751199
Drug: human umbilical cord mesenchymal stem cells
RxNorm normalized name: Human Umbilical Cord Mesenchymal Stem Cells
DrugBank: Human Umbilical Cord Mesenchymal Stem Cells (DB15726)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Portal vein infusion human umbilical cord mesenchymal stem cells
Trial: NCT06751199
Drug: allogeneic islet
RxNorm normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Portal vein infusion of allogeneic islet
Trial: NCT06762327
Drug: Ensartinib
RxNorm normalized name: Ensartinib
DrugBank: Ensartinib (DB14860)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ensartinib 225mg ,PO,QD,until disease progression or intolerable toxicity
Trial: NCT06762431
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose Level 1
Trial: NCT06762431
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose Level 2
Trial: NCT05699408
Drug: Insulin Glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin Glargine injected subcutaneously once daily. Treat-to-target dose titration during the trial
Trial: NCT06118034
Drug: Colchicine 0.5 MG
RxNorm normalized name: colchicine 0.5 MG
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Take 0.5mg of colchicine tablets orally for 3 days before surgery, and continued to take 0.5mg every other day (qod) for 10 days after tracheal extubation.
Trial: NCT05386121
Drug: Pethidine
RxNorm normalized name: Pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Will be given intravenously as a rescue analgesic (0.5 mg/kg with maximal dose 1.5 mg/kg) in both study groups if Children's Hospital Eastern Ontario Pain Scale (CHEOPS) more than 6. Quality of postoperative analgesia will be assessed using CHEOPS pain score at time transfer to PACU, 15, 30 minutes then 1, 2, 4, 6 hours postoperatively.
Trial: NCT05996185
Drug: Mogamulizumab
RxNorm normalized name: mogamulizumab
DrugBank: Mogamulizumab (DB12498)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mogamulizumab is a humanized monoclonal antibody directed against C-C chemokine receptor 4 (CCR4) with potential anti-inflammatory and antineoplastic activities. Mogamulizumab selectively binds to and blocks the activity of CCR4, which may inhibit CCR4-mediated signal transduction pathways and, so, chemokine-mediated cellular migration and proliferation of T cells, and chemokine-mediated angiogenesis.
Trial: NCT04056910
Drug: ivosidenib and nivolumab
RxNorm normalized name: ivosidenib
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ivosidenib will be administered orally at a dose of 500 mg (provided as 250 mg strength tablets) daily. The dose may be reduced to 250 mg for patients experiencing more than one event of Grade 2 nausea or vomiting (related or unrelated), or Grade 3 or Grade 4 adverse events. Nivolumab will be administered at 480 mg IV every 28 days.
Trial: NCT06577558
Drug: SR1375 capsule 3mg+regular treatments
RxNorm normalized name: Insulina regular
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SR1375 capsule 3mg QD orally+CAP regular treatments
Trial: NCT06577558
Drug: SR1375 capsule 1mg+regular treatments
RxNorm normalized name: Insulina regular
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SR1375 capsule 1mg QD orally+CAP regular treatments
Trial: NCT05750290
Drug: CKD-702 in combination with irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: CKD-702 and irinotecan will be intravenously administered every 2 weeks.
Trial: NCT05071118
Drug: Pregabalin 150mg
RxNorm normalized name: PREGABALIN 150MG CAP,UD
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: pregabalin patients (group P) received capsules containing 150mg of pregabalin in the ward then transferred to OR to receive spinal anesthesia before surgery
Trial: NCT06176196
Drug: VX-548
RxNorm normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets for oral administration.
Trial: NCT04943198
Drug: Vemurafenib
RxNorm normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg/kg/day
Trial: NCT06089551
Drug: SmofKabiven
DrugBank: Histidine (DB00117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive supplementary parenteral nutrition based on their calorie intake. The dosage will be adjusted on a daily basis depending on intake.
Trial: NCT06237205
Drug: Niraparib
RxNorm normalized name: Niraparib
DrugBank: Niraparib (DB11793)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: a highly selective PARP1 and PARP2 inhibitor
Trial: NCT04712279
Drug: Ivermectin 0.6mg/kg/day
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Use of ivermectin 0.6m/kg/day q.d.for 05 days
Trial: NCT04712279
Drug: Ivermectin 1.0mg/kg/day
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ivermectin 1.0mg/kg/day q.d. for 05 days
Trial: NCT04712279
Drug: Hydroxychloroquine
RxNorm normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine 200mg/day q.d. for 05 days
Trial: NCT06669572
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks.~Pembrolizumab will be given for a maximum of 2 years (total 35 cycles) with dosing every 3 weeks.
Trial: NCT06669572
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenvatinib will be taken once daily, with or without food, at the same time each day.
Trial: NCT04915183
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will be provided with atorvastatin (40 mg) or placebo to be taken daily by mouth or by feeding tube. The tablets may be taken whole or crushed according to patient swallowing capabilities and preference.
Trial: NCT00627835
Drug: sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cohort 1 - sorafenib 200 mg PO bid concurrent with radiation
Trial: NCT06766565
Drug: QYJD Compound Preparation
RxNorm normalized name: compound benzoin tincture (USP) / Podophyllum preparation
DrugBank: Benzoin (DB14020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The intervention group was treated with 2 capsules (g) of expelling stasis and QYJD compound preparation orally for 4 days before thoracoscopic radical surgery for lung cancer, 3 times a day. The blank control group had no oral drug treatment before surgery.
Trial: NCT06787183
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 130mg/m2, d1, q3w, 2 cycles
Trial: NCT06787183
Drug: QL1706
RxNorm normalized name: QL1706
DrugBank: QL1706 (DB17562)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.0 mg/kg, q3w
Trial: NCT00627835
Drug: sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: o Cohort 2 - sorafenib 400 mg PO bid concurrent with radiation
Trial: NCT00627835
Drug: sorafenib and cisplatin
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cohort 3 - sorafenib 200 mg PO bid / cisplatin 75 mg/m2 weeks 1, 4 and 7
Trial: NCT00627835
Drug: sorafenib and cisplatin
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: o Cohort 4 - sorafenib 400 mg PO bid/ cisplatin 75 mg/m2 weeks 1, 4 and 7
Trial: NCT00627835
Drug: sorafenib and cisplatin
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cohort 5 - sorafenib 400 mg PO bid/ cisplatin 100 mg/m2 weeks 1, 4 and 7
Trial: NCT06355401
Drug: Tamoxifen 20mg
RxNorm normalized name: tamoxifen 20 MG
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: maintenance TAM 20 mg daily for DLBCL who achieve CR after chemotherapy and/or radiotherapy and/or BMT
Trial: NCT06054321
Drug: stepwise pharmacotherapy
RxNorm normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In the stepwise pharmacotherapy group, treatment strategies (augmentation with antipsychotics (aripiprazole), augmentation with mood stabilizer (lithium),combination (mirtazapine)) will be determined every 3 weeks.
Trial: NCT06769295
Drug: AK112
RxNorm normalized name: IMMUNOGLOBULIN G1 (240-ALANINE,241-ALANINE), ANTI-(HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR A) (HUMAN-MUS MUSCULUS MONOCLONAL AK112 .GAMMA.1-CHAIN) FUSION PROTEIN WITH PEPTIDE LINKER (GGGS)4 FUSION PROTEIN WITH IMMUNOGLOBULIN ANTI-(HUMAN PROGRAMMED CELL
DrugBank: Ivonescimab (DB18931)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: non-Squamous NSCLC with malignant pleura effusions:Subjects receive AK112 plus Pemetrexed and Carboplatin/Cisplatin on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK112 plus Pemetrexed until progression.
Trial: NCT06768268
Drug: Mannitol (20%)
RxNorm normalized name: Mannitol
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adding Mannitol into Voluven and used as solvent of ICG
Trial: NCT06767358
Drug: ketamine hydrochloride
RxNorm normalized name: Ketamine Hydrochloride
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous adjunctive ketamine infusion at a fixed dose of 0.50mg/kg/hour
Trial: NCT06702124
Drug: Rotigotine 4Mg/24Hrs Patch
RxNorm normalized name: ROTIGOTINE 4MG/24HRS PATCH
DrugBank: Rotigotine (DB05271)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rotigotine 4 mg/24Hrs administration for 24 weeks
Trial: NCT05899816
Drug: Rocatinlimab
RxNorm normalized name: Rocatinlimab
DrugBank: Rocatinlimab (DB18809)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) injection
Trial: NCT05641558
Drug: 611 150mg
RxNorm normalized name: 11-(3-Dimethylaminopropylidene)-6,11-dihydrodibenzo(b,e)thiepin
DrugBank: Dosulepin (DB09167)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection, 150 mg (single dose treatment period) + 300mg (loading dose, week 0) + 150mg QW (maintenance dose, from Week 1 to Week 15, 15 cycles)
Trial: NCT05641558
Drug: 611 300mg
RxNorm normalized name: 11-(3-Dimethylaminopropylidene)-6,11-dihydrodibenzo(b,e)thiepin
DrugBank: Dosulepin (DB09167)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection, 300 mg (single dose treatment period) + 600mg (loading dose, week 0) + 300mg Q2W (maintenance dose, from Week 1 to Week 15, 8 cycles)
Trial: NCT05641558
Drug: 611 600mg
RxNorm normalized name: 11-(3-Dimethylaminopropylidene)-6,11-dihydrodibenzo(b,e)thiepin
DrugBank: Dosulepin (DB09167)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection, 600 mg (single dose treatment period) + 600mg (loading dose, week 0) + 300mg QW (maintenance dose, from Week 1 to Week 15, 15 cycles)
Trial: NCT06379217
Drug: GnRH antagonists
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: abarelix, degarelix, or relugolix
Trial: NCT06379217
Drug: Metoclopramide
RxNorm normalized name: Metoclopramide
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ATC code A03FA01
Trial: NCT06560138
Drug: SHR-4602
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-4602 will be administered through IV infusion.
Trial: NCT06706284
Drug: Semaglutide Injectable Product
RxNorm normalized name: semaglutide Injectable Product
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: A GLP-1 inhibitor used to control T2DM
Trial: NCT06208540
Drug: Cerebrolysin
RxNorm normalized name: cerebrolysin
DrugBank: Cerebrolysin (DB16599)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerebrolysin Dose:5 ml ampoule (1ml contains 215.2 mg cerebrolysin) once daily through intramuscular injection five times per week, for a total of 20 treatments (for 4 weeks), after which the cycle was repeated again for at least 6 weeks till a maximum of 24 weeks.
Trial: NCT04599478
Drug: Naltrexone and Bupropion medication
RxNorm normalized name: bupropion and naltrexone
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NB medication will be taken daily in pill form.
Trial: NCT06734637
Drug: Peginterferon α-2b injection
RxNorm normalized name: peginterferon alfa-2b Injection
DrugBank: Peginterferon alfa-2b (DB00022)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive Peginterferon α-2b 180 mcg once a week and follow-up. Dose adjustments will be made by the investigator based on the type and severity of adverse event (AE).
Trial: NCT06789679
Drug: Gemcitabine, albumin-bound paclitaxel, S-1
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Albumin-bound paclitaxel：125mg/m2，ivgtt，D1，q2w Gem：1000mg/m2，ivgtt，D1，q2w S-1：40-60mg Bid，PO，d1-7，q2w
Trial: NCT06789679
Drug: Gemcitabine, albumin-bound paclitaxel
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Albumin-bound paclitaxel：125mg/m2，ivgtt，D1，D8，q3w Gem：1000mg/m2，ivgtt，D1，D8，q3w
Trial: NCT06787976
Drug: Dolutegravir (DTG)
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dolutegravir + Tenofovir Disoproxil Fumarate / Emtricitabine
Trial: NCT06787976
Drug: Darunavir/Cobicistat (FDC)
DrugBank: Darunavir (DB01264)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Darunavir Cobicistat + TDF/FTC
Trial: NCT05566795
Drug: Tovorafenib
RxNorm normalized name: Tovorafenib
DrugBank: Tovorafenib (DB15266)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral type II RAF kinase inhibitor
Trial: NCT06780462
Drug: Corticosteroids + Rivaroxaban
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Corticosteroids according to the schedule of reduction of prednisone (or equivalent prednisone dose only if prednisone is out of stock in the market) and Rivaroxaban
Trial: NCT06780462
Drug: Corticosteroids alone
RxNorm normalized name: abiraterone and corticosteroids
DrugBank: Abiraterone (DB05812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids according to the schedule of reduction of prednisone (or equivalent prednisone dose only if prednisone is out of stock in the market)
Trial: NCT06783257
Drug: Esomeprazole sodium for injection
RxNorm normalized name: Esomeprazole Sodium for Injection
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 80mg，iv，30±3min； Followed by 8 mg/h, ivd, 71.5 h
Trial: NCT05410860
Drug: Etripamil NS 70 mg
RxNorm normalized name: NS-2359
DrugBank: Etripamil (DB12605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etripamil NS 70 mg will be administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.
Trial: NCT06762860
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: label sticker
Trial: NCT06762860
Drug: Granisetron
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: label sticker
Trial: NCT06109155
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tranexamic acid will be used in two different doses (50mg/kg vs 20mg/kg). the tranexamic acid pump will start from the begin of anesthesia until all dose is administrated.
Trial: NCT06786026
Drug: bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: bevacizumab
Trial: NCT06786026
Drug: QL1706
RxNorm normalized name: QL1706
DrugBank: QL1706 (DB17562)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bispecific antibody (bsAB) targeting PD-1 and CLTA-4
Trial: NCT06786026
Drug: Nab paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: albumin-bound paclitaxel
Trial: NCT06787430
Drug: nicorandil
RxNorm normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the nicorandil group, intracoronary nicorandil 3mg dissolved in 3ml saline was given within 30 seconds at two time points, one was when the guidewire or ballon passed the lesion and the blood flow was regained, and another was the time before the stent was implanted.
Trial: NCT06787430
Drug: Saline (NaCl 0,9 %) (placebo)
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In the control group, 3ml saline was given intracoronary through the guiding catheter within 30 seconds at the same time points in nicorandil group.
Trial: NCT06787846
Drug: Active Comparator: Group HQ: Hydroquinone 4%
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cream : Application all over the face once a day (at bedtime) and Tinted sunscreen SPF 50+, twice a day
Trial: NCT06651567
Drug: ITI-1284
RxNorm normalized name: Arthur Itis
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ITI-1284 10 mg or 20 mg rapidly disintegrating tablet, taken once daily, sublingual administration
Trial: NCT04846881
Drug: Iclepertin
RxNorm normalized name: Iclepertin
DrugBank: Iclepertin (DB19058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iclepertin